Hepatitis C is an infection caused by a virus that attacks the liver and causes inflammation. An estimated 3.5 million Americans are living with hepatitis C, with about half unaware they even have it. Recent advancements in hepatitis C treatments have greatly improved. New medications can lead to a cure in about 90 percent of people. But the prices for such treatments are prohibiting access and that means more people will remain sick and sometimes die. The Centers for Disease Control and Prevention found that in 2014, hepatitis C related deaths reached an all-time high of 19,659, killing more Americans each year than all other infectious diseases combined, including HIV.
American consumers face skyrocketing out-of-pocket costs for their prescription medications. Senate Bill 2019 – The Preserve Access to Affordable Generics Act (S. 2019) would lower these costs by stopping the anticompetitive practice of “pay-for-delay” deals, also known as “reverse payment agreements.” These schemes enable brand-name pharmaceutical companies to pay-off potential generic competitors to postpone launching lower cost generic medications. The Federal Trade Commission has estimated that eliminating these agreements would save consumers about $3.5 billion a year.